<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108676</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-111</org_study_id>
    <nct_id>NCT04108676</nct_id>
  </id_info>
  <brief_title>Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects</brief_title>
  <official_title>a Single-center, One-arm, Open, and Fixed Sequences Study to Evaluate the Effects of Omeprazole on the Pharmacokinetics of Fluzoparib in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of&#xD;
      Fluzoparib in Healthy male Adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>repeated oral doses of Omeprazole on the pharmacokinetic profile of a single dose of Fluzoparib</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to t of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to infinity of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>AUC0-∞ (if available)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of Adverse Events Assessments</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>Adverse Events Assessments (NCI-CTC AE 5.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Fluzoparib Drug: Omeprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>PARP inhibitor</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>proton pump inhibitor</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 50 years (including both ends), male;&#xD;
&#xD;
          2. Male volunteers have a body weight ≥ 50.0 kg and a body mass index (BMI) between 19&#xD;
             and 28 kg/m2 (including both ends);&#xD;
&#xD;
          3. Male volunteers are willing to have no birth plans in the next 6 months and&#xD;
             voluntarily take effective contraceptive measures;&#xD;
&#xD;
          4. Volunteers voluntarily sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous or currently suffering from circulatory system (myocarditis, coronary heart&#xD;
             disease, pathological arrhythmia, stroke, etc.), endocrine system, nervous system,&#xD;
             digestive system (peptic ulcer, colitis, pancreatitis, etc.), respiratory system&#xD;
             (Invasive lung disease, pneumonia, dyspnea, etc., urogenital system (chronic kidney&#xD;
             disease, renal insufficiency, renal anemia), hematology, immunology, psychiatry and&#xD;
             metabolic abnormalities, etc. Result of any other disease;&#xD;
&#xD;
          2. A history of allergies to drugs, foods or other substances; allergies, including a&#xD;
             history of severe drug allergies or drug allergies; a history of allergies to&#xD;
             Fluzoparib capsules or omeprazole magnesium enteric-coated tablets&#xD;
&#xD;
          3. Those who have undergone surgery within 4 weeks prior to the trial or who plan to&#xD;
             undergo surgery during the study;&#xD;
&#xD;
          4. Those who have taken any drugs or health care products (including Chinese herbal&#xD;
             medicines) within 14 days before the test;&#xD;
&#xD;
          5. Any drug that inhibits or induces liver metabolism of the drug within 30 days prior to&#xD;
             the test (eg, inducer - barbiturate, carbamazepine, phenytoin, glucocorticoid,&#xD;
             omeprazole; inhibitor - SSRI resistance) Depressants, cimetidine, diltiazem,&#xD;
             macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones,&#xD;
             antihistamines;&#xD;
&#xD;
          6. Those who participated in any clinical trial and took any clinical trial drug within 3&#xD;
             months prior to the trial;&#xD;
&#xD;
          7. Donate blood or massive blood loss (≥200 mL), receive blood transfusion or use blood&#xD;
             products within 3 months before enrollment;&#xD;
&#xD;
          8. One or more non-pharmaceutical contraceptives cannot be used during the volunteer&#xD;
             trial;&#xD;
&#xD;
          9. Those who have special requirements for diet and cannot follow the unified diet;&#xD;
&#xD;
         10. Drink excessive amounts of tea, coffee and/or caffeinated beverages (8 cups or more, 1&#xD;
             cup = 250 mL) per day;&#xD;
&#xD;
         11. smokers or smokers with more than 5 cigarettes per day for the first 3 months of the&#xD;
             trial or who cannot stop using any tobacco products during the trial period;&#xD;
&#xD;
         12. Alcoholics or those who regularly drink alcohol within 6 months prior to the test, ie&#xD;
             drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of&#xD;
             40% alcohol or 150 mL of wine) or during the test period Stop using any alcoholic&#xD;
             products;&#xD;
&#xD;
         13. Drug abusers or soft drugs (eg marijuana) 3 months prior to the trial or hard drugs&#xD;
             (eg cocaine, phencyclidine, etc.) 1 year prior to the trial; and nicotinic positive&#xD;
             volunteers&#xD;
&#xD;
         14. Abnormal vital signs (systolic blood pressure &lt;90 mmHg or &gt;140 mmHg, diastolic blood&#xD;
             pressure &lt;50 mmHg or &gt;90 mmHg; pulse &lt;50 bpm or &gt;100 bpm) or physical examination,&#xD;
             electrocardiogram, laboratory examination, imaging examination abnormalities&#xD;
             Clinically significant (subject to the judgment of the clinical research doctor);&#xD;
&#xD;
         15. have a history of dysphagia or any history of gastrointestinal disease that affects&#xD;
             drug absorption;&#xD;
&#xD;
         16. Those who have undergone any surgery within the first 6 months of screening; have&#xD;
             previously undergone any surgery that affects gastrointestinal absorption (including&#xD;
             gastrectomy, bowel resection, stomach reduction surgery, etc.);&#xD;
&#xD;
         17. The volunteer refused to discontinue any beverage containing methylxanthine, such as&#xD;
             caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any juice, 48&#xD;
             hours before the study drug was administered until the end of the study;&#xD;
&#xD;
         18. Creatinine clearance (CLCr) &lt;80 mL/min, or creatinine above the upper limit of normal;&#xD;
&#xD;
         19. Volunteers may not be able to complete the study for other reasons or those the&#xD;
             investigator believes should not be included.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The third xiangya hospital Hospital,of central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

